Dr. Shalini Shenoy, M.D.
Claim this profileWashington University School of Medicine
About Shalini Shenoy, M.D.
Education:
- Obtained MD (Doctor of Medicine) from Washington University School of Medicine, St. Louis, MO.
- Completed Residency in Internal Medicine at Washington University School of Medicine.
- Undertook Fellowship in Hematology and Oncology at Washington University School of Medicine.
Experience:
- Specializes in hematology and oncology at the Siteman Cancer Center.
Area of expertise
Acute Myeloid Leukemia
Shalini Shenoy, M.D. has run 8 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Sickle Cell Disease
Shalini Shenoy, M.D. has run 5 trials for Sickle Cell Disease. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Washington University
Clinical Trials Shalini Shenoy, M.D. is currently running
Extended vs Short-Term Abatacept Dosing
for Graft-versus-Host Disease
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior to the fifth dose, patients will be randomly assigned to the 4-dose abatacept arm and receive 4 doses of placebo or 8-dose abatacept arm and receive 4 more doses of abatacept. The primary endpoint of the study will be severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS). The study will end when the last patient has reached 2 years after transplant. Results will first be calculated and the study unblinded when the last patient has reached one year post-transplant.
Recruiting
0 awards
Phase 2
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting
1 award
Phase 1 & 2
13 criteria
More about Shalini Shenoy, M.D.
Clinical Trial Related
4 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 14 Active Clinical Trials
Treatments Shalini Shenoy, M.D. has experience with
- Fludarabine
- Melphalan
- Cyclophosphamide
- Cytarabine
- GVHD Prophylaxis Regimen
- RIC Regimen
Breakdown of trials Shalini Shenoy, M.D. has run
Acute Myeloid Leukemia
Sickle Cell Disease
Hemangioblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shalini Shenoy, M.D. specialize in?
Shalini Shenoy, M.D. focuses on Acute Myeloid Leukemia and Sickle Cell Disease. In particular, much of their work with Acute Myeloid Leukemia has involved FLT3 positive patients, or patients who are Stage II.
Is Shalini Shenoy, M.D. currently recruiting for clinical trials?
Yes, Shalini Shenoy, M.D. is currently recruiting for 14 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Shalini Shenoy, M.D. has studied deeply?
Yes, Shalini Shenoy, M.D. has studied treatments such as Fludarabine, Melphalan, Cyclophosphamide.
What is the best way to schedule an appointment with Shalini Shenoy, M.D.?
Apply for one of the trials that Shalini Shenoy, M.D. is conducting.
What is the office address of Shalini Shenoy, M.D.?
The office of Shalini Shenoy, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.